Cite
HARVARD Citation
Du, X. et al. (2018). Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study. Asia-Pacific journal of clinical oncology. 14 (3), pp. 270-278. [Online].